stachydrine has been researched along with Liver Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bao, X; Chen, Q; Chen, S; Han, X; Huang, J; Liu, Y; Qiu, Y; Sheng, H; Wang, T; Yin, S; Yu, H; Zhang, C | 1 |
| Chen, X; Yan, N | 1 |
2 other study(ies) available for stachydrine and Liver Neoplasms
| Article | Year |
|---|---|
Stachydrine hydrochloride inhibits hepatocellular carcinoma progression via LIF/AMPK axis.
Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Humans; Liver Neoplasms; Mice; Molecular Docking Simulation; Proline | 2022 |
Stachydrine inhibits TGF-β1-induced epithelial-mesenchymal transition in hepatocellular carcinoma cells through the TGF-β/Smad and PI3K/Akt/mTOR signaling pathways.
Topics: Cadherins; Carcinoma, Hepatocellular; Cell Movement; Cell Survival; Dose-Response Relationship, Drug; Epithelial-Mesenchymal Transition; Hep G2 Cells; Humans; Liver Neoplasms; Phosphatidylinositol 3-Kinases; Proline; Signal Transduction; Smad2 Protein; TOR Serine-Threonine Kinases; Transforming Growth Factor beta1; Vimentin | 2021 |